Results 121 to 130 of about 6,900 (178)

Mouse Model of Graves' Orbitopathy in Current Research and Future Perspectives. [PDF]

Medicina (Kaunas)
Lee GM, Jung WH, Kim Y, Oh MI, Jang SY.
europepmc   +1 more source

Lamina cribrosa curvature depth and index as novel parameters in Graves' ophthalmopathy. [PDF]

Sci Rep
Ergen A, Yılmaz Tuğan B.
europepmc   +1 more source

Expression and significance of IL-27 and IL-35 in orbital fat in patients with severe TAO. [PDF]

Diagn Pathol
Wang B, Xu Z, Zhao X, Zhang L, Zhang H.
europepmc   +1 more source

Application of protein A immunoadsorption in thyroid-associated ophthalmopathy (TAO): study protocol for a non-randomised controlled clinical trial. [PDF]

BMJ Open
Lu S, Chen H, Liu S, Zhang F, Xiong W.
europepmc   +1 more source

The role of the FT3/FT4 ratio in predicting remission and relapse in pediatric Graves' disease. [PDF]

Eur J Pediatr
Kara L, Siraz UG, Cicek D, Sarikaya E, Gok E, Berber U, Kendirci M, Kurtoğlu S, Hatipoglu N.   +8 more
europepmc   +1 more source

Emerging therapeutic approaches in graves' ophthalmopathy: an update on pharmacological interventions. [PDF]

Front Immunol
Wang L, Chen L.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Ophthalmopathy of Graves' Disease

Annual Review of Medicine, 1992
Ophthalmopathy is an integral component of Graves’ disease. It usually appears at the same time as hyperthyroidism, and is characterized by proptosis (exophthalmos), periorbital and conjunctival edema, eye muscle dysfunction, and on occasion corneal ulceration or optic neuropathy.
J A, Carter, R D, Utiger
exaly   +3 more sources